Nasdaq · CIK 0002131524
BRVE Braveheart Bio, Inc.
Insider trading from SEC Form 4. Last filing Aug 11, 2026. Close $20.36 on Oct 12, 2026, +10% from the 52-week low and -32% from the high.
In brief
Braveheart Bio, Inc. (BRVE) has 14 SEC Form 4 filings on file from 13 insiders, the latest filed on Aug 11, 2026. In the last 90 days insiders made 10 open-market buys worth $159M and 0 open-market sells worth $0, net +$159M.
10 open-market trades have been scored at BRVE. The newest: AH Bio Fund IV, L.P. (10% owner) bought $20M of stock on Aug 7, 2026, filed Aug 11, 2026, scored 50 (moderate). The largest of the 10 shown: Forbion Growth Opportunities Fund III Cooperatief U.A. (10% owner) bought $65M on Aug 7, 2026, scored 53 (moderate). 10 insiders bought within 14 days of each other around Aug 7, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Braveheart Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | AH Bio Fund IV, L.P. owner buy | $20M 1,100,000 shares | +12% | - | |
| 53Moderate | Orbimed Advisors LLC director, owner buy | $35M 1,940,000 shares | +19% | - | |
| 58Moderate | Erez Chimovits director, owner buy | $35M 1,940,000 shares | +19% | - | |
| 25Weak | Michele A. Anderson Chief Development Officer buy | $20k 1,111 shares | +0% | - | |
| 53Moderate | Forbion Growth Opportunities Fund III Cooperatief U.A. owner buy | $65M 3,600,000 shares | +37% | - | |
| 63Notable | David Charles Lubner director buy | $1000k 55,555 shares | - | - | |
| 65Notable | Travis Murdoch CEO and President buy | $1.5M 83,333 shares | +3% | - | |
| 33Weak | David I Malek director buy | $75k 4,166 shares | +1% | - | |
| 58Moderate | Christopher Viehbacher director buy | $1.5M 83,333 shares | +16% | - | |
| 58Moderate | James Paul Rickey Chief Financial Officer buy | $500k 27,777 shares | +6% | - |
Transactions
Every row filed, 34 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | AH Bio Fund IV, L.P. owner | CConversion Common Stockindirect: By AH Bio Fund IV, L.P. | +9,132,420 | - | - | 9,132,420 | Aug 11, 2026 |
| Aug 7, 2026 | Erez Chimovits director, owner | CConversion Common Stockindirect: See footnotes | +9,132,420 | - | - | 10,235,159 | Aug 11, 2026 |
| Aug 7, 2026 | Orbimed Advisors LLC director, owner | CConversion Common Stockindirect: See footnotes | +9,132,420 | - | - | 10,235,159 | Aug 11, 2026 |
| Aug 7, 2026 | AH Bio Fund IV, L.P. owner | POpen-market purchase Common Stockindirect: By AH Bio Fund IV, L.P. | +1,100,000 | $18.00 | $20M | 10,232,420 | Aug 11, 2026 |
| Aug 7, 2026 | Erez Chimovits director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,666,667 | $18.00 | $30M | 11,901,826 | Aug 11, 2026 |
| Aug 7, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,666,667 | $18.00 | $30M | 11,901,826 | Aug 11, 2026 |
| Aug 7, 2026 | Erez Chimovits director, owner | POpen-market purchase Common Stockindirect: See footnotes | +273,333 | $18.00 | $4.9M | 273,333 | Aug 11, 2026 |
| Aug 7, 2026 | AH Bio Fund IV, L.P. owner | CConversion Series A Preferred Stockderivativeindirect: By AH Bio Fund IV, L.P. | -40,000,000 | $0.00 | $0 | 0 | Aug 11, 2026 |
| Aug 7, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +273,333 | $18.00 | $4.9M | 273,333 | Aug 11, 2026 |
| Aug 7, 2026 | Erez Chimovits director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -40,000,000 | $0.00 | $0 | 0 | Aug 11, 2026 |
| Aug 7, 2026 | Orbimed Advisors LLC director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -40,000,000 | $0.00 | $0 | 0 | Aug 11, 2026 |
| Aug 7, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Common Stock | +7,420,091 | - | - | 7,420,091 | Aug 10, 2026 |
| Aug 7, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Non-voting Series A preferred stockderivative | -32,500,000 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 5, 2026 | Jasper Bos director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 7, 2026 |
| Aug 7, 2026 | Michele A. Anderson Chief Development Officer | POpen-market purchase Common Stock | +1,111 | $18.00 | $20k | 332,161 | Aug 7, 2026 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Common Stock | +9,132,420 | $0.00 | $0 | 9,720,546 | Aug 7, 2026 |
| Aug 7, 2026 | James Paul Rickey Chief Financial Officer | POpen-market purchase Common Stock | +27,777 | $18.00 | $500k | 520,927 | Aug 7, 2026 |
| Aug 7, 2026 | Christopher Viehbacher director | POpen-market purchase Common Stock | +83,333 | $18.00 | $1.5M | 609,519 | Aug 7, 2026 |
| Aug 7, 2026 | David I Malek director | POpen-market purchase Common Stock | +4,166 | $18.00 | $75k | 533,845 | Aug 7, 2026 |
| Aug 7, 2026 | Travis Murdoch CEO and President | POpen-market purchase Common Stock | +83,333 | $18.00 | $1.5M | 2,940,670 | Aug 7, 2026 |
| Aug 7, 2026 | David Charles Lubner director | POpen-market purchase Common Stock | +55,555 | $18.00 | $1000k | 55,555 | Aug 7, 2026 |
| Aug 5, 2026 | Erez Chimovits director, owner | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 7, 2026 |
| Aug 5, 2026 | Tim Lohoff director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 7, 2026 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Common Stockindirect: By Forbion Ventures Fund VII Cooperatief U.A. | +7,990,867 | $0.00 | $0 | 8,505,478 | Aug 7, 2026 |
| Aug 5, 2026 | David Charles Lubner director | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Aug 7, 2026 |
| Aug 5, 2026 | Michele A. Anderson Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Aug 7, 2026 |
| Aug 5, 2026 | Christopher Viehbacher director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 7, 2026 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | POpen-market purchase Common Stock | +1,920,000 | $18.00 | $35M | 11,640,546 | Aug 7, 2026 |
| Aug 5, 2026 | James Paul Rickey Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Aug 7, 2026 |
| Aug 5, 2026 | David I Malek director | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 7, 2026 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | POpen-market purchase Common Stockindirect: By Forbion Ventures Fund VII Cooperatief U.A. | +1,680,000 | $18.00 | $30M | 10,185,478 | Aug 7, 2026 |
| Aug 5, 2026 | Travis Murdoch CEO and President | AGrant or award Stock Option (Right to Buy)derivative | +550,000 | $0.00 | $0 | 550,000 | Aug 7, 2026 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Series A Preferred Stockderivative | -40,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. owner | CConversion Series A Preferred Stockderivativeindirect: By Forbion Ventures Fund VII Cooperatief U.A. | -35,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- AH Bio Fund IV, L.P.owner
- Michele A. AndersonChief Development Officer
- Jasper Bosdirector
- Erez Chimovitsdirector, owner
- Forbion Growth Opportunities Fund III Cooperatief U.A.owner
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.owner
- Tim Lohoffdirector
- David Charles Lubnerdirector
- David I Malekdirector
- Travis MurdochCEO and President
- Orbimed Advisors LLCdirector, owner
- James Paul RickeyChief Financial Officer
- Christopher Viehbacherceo, president, officer, director
Questions about BRVE
Answered from the filings on this page, as of the latest one.
Are insiders buying BRVE?
As of Aug 11, 2026, SEC Form 4 filings show 10 open-market buys worth $159M by 10 insiders and 0 open-market sells worth $0 by 0 insiders at Braveheart Bio, Inc. in the last 90 days, net +$159M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade BRVE on the open market?
AH Bio Fund IV, L.P. (10% owner) bought $20M of BRVE on Aug 7, 2026 and filed the Form 4 on Aug 11, 2026. InsiderTell scored 50 (moderate), with 10 insiders on the same side within 14 days.
How many insiders file Form 4 at Braveheart Bio, Inc.?
13 people have filed a Form 4 at Braveheart Bio, Inc., among them AH Bio Fund IV, L.P. (10% owner), Michele A. Anderson (Chief Development Officer), Jasper Bos (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.